Antitumor necrosis factor, infliximab, and adalimumab: use with caution in eosinophilic bowel disease

J Pediatr Gastroenterol Nutr. 2013 Oct;57(4):e25. doi: 10.1097/MPG.0b013e3182a1e13b.

Authors

Glenn T Furuta¹, Dan Atkins, Kelley E Capocelli, Edwin F de Zoeten, David Fleischer, Calies Menard-Katcher

Affiliation

¹ *Section of Pediatric Gastroenterology, Hepatology, Digestive Health Institute, Children's Hospital Colorado †Department of Pediatrics ‡Department of Pathology, National Jewish Health, Aurora, CO.

PMID: 23820407
DOI: 10.1097/MPG.0b013e3182a1e13b

No abstract available

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized / therapeutic use*
Enterocolitis / drug therapy*
Eosinophilia / drug therapy*
Female
Humans
Inflammatory Bowel Diseases / drug therapy*
Male
Tumor Necrosis Factor-alpha / antagonists & inhibitors*

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Tumor Necrosis Factor-alpha